Search research articles
Contact Us
Filters
Showing results (131-140 of 338) with videos related to
Page
of 34
Sort By:
The Oncologist
|
February 6, 2025
Updated overall survival in patients with prior checkpoint inhibitor therapy in the phase III TIVO-3 study
Miguel Zugman, David F McDermott, Bernard J Escudier, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 19, 2012
Phase III trial of carboplatin and paclitaxel with or without sorafenib in metastatic melanoma
Keith T Flaherty, Sandra J Lee, Fengmin Zhao, et al.
Cancer Medicine
|
October 11, 2017
High frequency of brain metastases after adjuvant therapy for high-risk melanoma
Wolfram E Samlowski, James Moon, Merle Witter, et al.
Frontiers in Oncology
|
January 31, 2022
Volume of Disease as a Predictor for Clinical Outcomes in Patients With Melanoma Brain Metastases Treated With Stereotactic Radiosurgery and Immune Checkpoint Therapy
Aidan M Burke, Michael Carrasquilla, Walter C Jean, et al.
Cancer
|
October 7, 2015
Cardiovascular toxicity after antiangiogenic therapy in persons older than 65 years with advanced renal cell carcinoma
Sekwon Jang, Chaoyi Zheng, Huei-Ting Tsai, et al.
AJR. American Journal of Roentgenology
|
June 20, 2008
Perfusion MDCT enables early detection of therapeutic response to antiangiogenic therapy
Adeel Sabir, Rachel Schor-Bardach, Carol J Wilcox, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
July 13, 2022
The Risk of Opportunistic Infections and the Role of Antibiotic Prophylaxis in Patients on Checkpoint Inhibitors Requiring Steroids
Neil J Shah, Michael R Cook, Tianmin Wu, et al.
JCO Oncology Practice
|
July 14, 2025
Long-Term Performance of Prognostic Models for Advanced Renal Cell Carcinoma in the Era of Improved Survival With Immune Checkpoint Inhibitors
Charlene M Mantia, Opeyemi A Jegede, David F McDermott, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 28, 2003
Phase I trial of concurrent twice-weekly recombinant human interleukin-12 plus low-dose IL-2 in patients with melanoma or renal cell carcinoma
Jared A Gollob, Korina G Veenstra, Robert A Parker, et al.
The Oncologist
|
December 28, 2022
Tivozanib in Patients with Advanced Renal Cell Carcinoma Previously Treated With Axitinib: Subgroup Analysis from TIVO-3
Luis Meza, David F McDermott, Bernard Escudier, et al.
Page
of 34
Search research articles
Search
Showing results (131-140 of 338) with videos related to
Sort By:
Page
of 34
The Oncologist
|
February 6, 2025
Updated overall survival in patients with prior checkpoint inhibitor therapy in the phase III TIVO-3 study
Miguel Zugman, David F McDermott, Bernard J Escudier, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 19, 2012
Phase III trial of carboplatin and paclitaxel with or without sorafenib in metastatic melanoma
Keith T Flaherty, Sandra J Lee, Fengmin Zhao, et al.
Cancer Medicine
|
October 11, 2017
High frequency of brain metastases after adjuvant therapy for high-risk melanoma
Wolfram E Samlowski, James Moon, Merle Witter, et al.
Frontiers in Oncology
|
January 31, 2022
Volume of Disease as a Predictor for Clinical Outcomes in Patients With Melanoma Brain Metastases Treated With Stereotactic Radiosurgery and Immune Checkpoint Therapy
Aidan M Burke, Michael Carrasquilla, Walter C Jean, et al.
Cancer
|
October 7, 2015
Cardiovascular toxicity after antiangiogenic therapy in persons older than 65 years with advanced renal cell carcinoma
Sekwon Jang, Chaoyi Zheng, Huei-Ting Tsai, et al.
AJR. American Journal of Roentgenology
|
June 20, 2008
Perfusion MDCT enables early detection of therapeutic response to antiangiogenic therapy
Adeel Sabir, Rachel Schor-Bardach, Carol J Wilcox, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
July 13, 2022
The Risk of Opportunistic Infections and the Role of Antibiotic Prophylaxis in Patients on Checkpoint Inhibitors Requiring Steroids
Neil J Shah, Michael R Cook, Tianmin Wu, et al.
JCO Oncology Practice
|
July 14, 2025
Long-Term Performance of Prognostic Models for Advanced Renal Cell Carcinoma in the Era of Improved Survival With Immune Checkpoint Inhibitors
Charlene M Mantia, Opeyemi A Jegede, David F McDermott, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 28, 2003
Phase I trial of concurrent twice-weekly recombinant human interleukin-12 plus low-dose IL-2 in patients with melanoma or renal cell carcinoma
Jared A Gollob, Korina G Veenstra, Robert A Parker, et al.
The Oncologist
|
December 28, 2022
Tivozanib in Patients with Advanced Renal Cell Carcinoma Previously Treated With Axitinib: Subgroup Analysis from TIVO-3
Luis Meza, David F McDermott, Bernard Escudier, et al.
Page
of 34